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A Large Mutational Study in Pachyonychia Congenita
Neil J. Wilson1, Sancy A. Leachman2, C. David Hansen2, Alexandra C. McMullan1, Leonard M. Milstone3,
Mary E. Schwartz4, W.H. Irwin McLean1, Peter R. Hull5 and Frances J.D. Smith1
Pachyonychia congenita (PC) is a rare autosomal dominant skin disorder characterized predominantly by nail
dystrophy and painful palmoplantar keratoderma. Additional clinical features include oral leukokeratosis,
follicular keratosis, and cysts (steatocysts and pilosebaceous cysts). PC is due to heterozygous mutations in one
of four keratin genes, namely, KRT6A, KRT6B, KRT16, or KRT17. Here, we report genetic analysis of 90 new
families with PC in which we identified mutations in KRT6A, KRT6B, KRT16, or KRT17, thereby confirming their
clinical diagnosis. A total of 21 previously unreported and 22 known mutations were found. Approximately half
of the kindreds had mutations in KRT6A (52%), 28% had mutations in KRT16, 17% in KRT17, and 3% of families
had mutations in KRT6B. Most of the mutations were heterozygous missense or small in-frame insertion/
deletion mutations occurring within one of the helix boundary motif regions of the keratin polypeptide. More
unusual mutations included heterozygous splice site mutations, nonsense mutations, and a 1-bp insertion
mutation, leading to a frameshift and premature termination codon. This study, together with previously
reported mutations, identifies mutation hotspot codons that may be useful in the development of personalized
medicine for PC.
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INTRODUCTION
Pachyonychia congenita (PC) is a rare genetic skin disorder
that is associated with mutations in one of four keratin genes,
KRT6A, KRT6B, KRT16 or KRT17 (Bowden et al., 1995;
McLean et al., 1995; Smith et al., 1998). The most striking
feature of PC is the painful and debilitating plantar
keratoderma (Figure 1). The mechanism underlying the
plantar pain is poorly understood; however, the formation
of blisters beneath the keratoderma is likely to be a major
contributing factor. Palmar keratoderma is less frequent. Nail
dystrophy presents in variable forms, from very minor or
almost absent nail changes through to the classic hyper-
trophic nail dystrophy that gives the condition its name
(Leachman et al., 2005; Figure 1). Other epithelial structures
can be affected, particularly the mucosae and the piloseba-
cesous unit. A more detailed description of the disorder is
given in McLean et al. (2011).
Historically, PC has been subdivided into two subtypes,
PC-1 (Jadassohn–Lewandowski type) or PC-2 (Jackson–Lawler
type), on the basis of the clinical presentation alone
(Jadassohn and Lewandowski, 1906; Jackson and Lawler,
1951). A combination of factors have led to the suggestion
that PC should be reclassified. First, the advent of molecular
genetics and the identification of the genes causing PC
provide a rational means of classifying patients. Second,
clinical analysis of the large case series collected by the
International Pachyonychia Congenita Research Registry
(IPCRR), fully linked to molecular genetic data, has shown
that there is considerable phenotypic overlap between the
historical PC-1 and PC-2 subtypes (Eliason et al., unpublished).
Thus, a new molecular genetic classification has been
adopted, fully supported by members of the International
Pachyonychia Congenita Consortium, whereby the subtypes
of PC refer to the mutated keratin gene (PC-6a for a patient
carrying a K6a mutation, PC-6b, PC-16, PC-17, and so on).
The designation ‘PC-U’ is used for cases where the causative
gene is unknown (McLean et al., 2011). The new classifica-
tion will (a) help discourage publication of spurious case
reports lacking molecular data (often with misdiagnosed
cases or cases with coincidental findings unrelated to PC)
and (b) allow better prognostic predictions and patient
counseling, especially when referenced to the IPCRR clinical
data set.
The 54 human keratins belong to the intermediate filament
protein family that consists of at least six types; keratins make
up the type I and type II intermediate filament proteins. A
major function of keratins is to form structural cytoskeletal
networks within epithelial cells that allow cells to withstand
everyday stress and physical trauma. Keratins are expressed
in pairs in tissue-specific and differentiation-specific
patterns (Lane, 1993). The keratins associated with PC,
K6a, and K16, K6b and K17 are predominantly expressed
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in basal/suprabasal layers of palmoplantar skin, as well as in
epidermal appendages and oral mucosa. In PC, these
epithelial cell compartments are rendered fragile by the
expression of dominant-negative mutant keratins. All cases of
PC with a confirmed molecular diagnosis, including those in
the literature, http://www.interfil.org (Szeverenyi et al.,
2008), and those in this study, are due to heterozygous
dominant-negative mutations, inherited as an autosomal
dominant trait. Although there are a small number of case
reports of PC with recessive inheritance in the literature, there
are no reports of recessive PC with a confirmed molecular
diagnosis.
All keratins share a common protein structure consisting of
a central a-helical rod domain of 310 amino acids subdivided
into the 1A, 1B, 2A, and 2B domains. These domains are
connected by non-helical linker regions, L1, L12, and L2. The
rod domain is flanked by short regions of sequence homology
(H1 and H2 regions), followed by the variable, non-helical
head (V1) and tail domains (V2). At either end of the rod
domain are the helix boundary motifs (the helix initiation
motif and the helix termination motif). These highly
conserved motifs are thought to be important in mediating
end-to-end interactions during filament assembly. The
majority of mutations in PC occur in these helix boundary
motifs, emphasizing the critical importance of these se-
quences for correct keratin filament formation and the
mechanical resilience of epithelial cells.
The IPCRR was established in 2004 by the patient
advocacy group, Pachyonychia Congenita Project (http://
www.pachyonychia.org). At the time of writing, 478 families
are registered (928 individuals), 223 families have completed
the detailed questionnaire (Eliason et al., unpublished) and
199 families have undergone genetic testing. Genetic testing
results from some of these cases have been previously
published (McLean et al., 1995; Smith et al., 1997, 2000,
2005; Liao et al., 2007a; Oh Adib et al., 2008; Cogulu et al.,
2009; Gruber et al., 2009).
Here, we present the findings of 90 new families with
mutations in KRT6A, KRT6B, KRT16, or KRT17. Within this
case series, we identified 21 previously unreported mutations
(22 families) and 22 known mutations (68 families). This
mutation analysis study not only confirms the clinical
diagnosis of these individuals but, together with previously
reported mutations (http://www.interfil.org), also identifies
mutation hotspot codons that may be useful in the develop-
ment of future allele-specific therapies.
RESULTS
Clinical details
All individuals involved in this study were recruited through
the IPCRR, an ongoing research program to identify PC
patients worldwide. This research registry is approved by an
institutional review board that complies with all principles of




K16 p.Asn125Ser K16 p.Arg127Pro K16 p.Arg127Pro K17 p.Asn92_Leu99del
K6a p.Leu468Pro
K6a p.Asn171Lys (siblings)
Figure 1. Clinical features of pachyonychia congenita (PC). Plantar keratoderma and nail dystrophy in PC patients with known keratin mutations. Mutations are
annotated. Note the variation in severity and clinical appearance of these features.
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important part of this study was the detailed clinical
consultations that were performed for all cases analyzed.
This bank of data allows us now, and in the future as the
number of cases analyzed increases, to identify any useful
genotype–phenotype correlation for PC. The predominant
clinical features of individuals involved in this study are
summarized in Supplementary Table S1 online. Of the 90
families analyzed, 36 represent familial occurrence of PC,
with many showing autosomal dominant inheritance
through several generations; the remaining 54 cases represent
spontaneous mutations.
Both common and rare dominant mutations cause PC
Within this large PC case series, pathogenic mutations were
identified in the KRT6A gene in approximately half (52%) of
the kindreds, whereas 28% had mutations in KRT16, 17%
had defects in KRT17, and 3% had mutations in KRT6B (see
Figure 2 and Supplementary Table S1 online). Mutations in
KRT6A also account for B50% of previously reported cases
of PC (http://www.interfil.org), consistent with our finding
here that this is the predominant PC gene. The majority of the
mutations we identified in all four genes were heterozygous
missense mutations occurring within one of the helix
boundary motif regions. In addition, we found some
small in-frame insertion/deletion mutations and, in particular,
the common K6a p.N172del mutation was identified in
16 families.
An unusual V2 domain mutation in one PC family
A more unusual mutation identified was a 1-bp insertion
in exon 9 of KRT6A, the last exon of this gene (K6a
c.1511_1512insG). This insertion results in a frameshift and
a premature stop codon just two amino acids upstream of the
natural stop codon, whereby the last 60 amino acids of the
K6a V2 domain are exchanged for a foreign peptide of 58
amino acids. Protein–protein BLAST (basic local alignment
search tool) analysis showed that this mutant peptide
sequence has no significant similarity to any human protein
(data not shown; http://blast.ncbi.nlm.nih.gov/). Kyte–Doolit-
tle hydrophilicity analysis revealed that the normal K6a V2
domain consists of alternating hydrophobic and hydrophilic
sequences, followed by a short hydrophilic C terminus
(Figure 3), consistent with the glycine-loop structure
proposed by Steinert for keratin variable domains (Korge
et al., 1992). In contrast, the mutant V2 domain is almost













Figure 2. Mutational spectrum in pachyonychia congenita (PC). Pie chart
showing percentage of families in this study with mutations in the four keratin
genes, namely, KRT6A, KRT6B, KRT16, and KRT17.
a Normal K6a V2 domain
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Figure 3. Kyte–Doolittle hydrophilicity analysis of normal and mutant K6a V2 domain. (a) The normal K6a V2 domain consists of alternating hydrophobic and
hydrophilic sequences, followed by a short hydrophilic C terminus, whereas (b) the mutant V2 domain is almost completely hydrophilic.
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secondary structure predicted by Robson–Garnier analysis,
the normal K6a V2 domain is predicted to adopt three large
areas of sheet conformations, separated by short regions
predicted to adopt turn conformations (Figure 3). This
contrasts with the mutant V2 domain, which is predicted to
consist largely of turn conformation with one helical region
near the C terminus (Figure 3). This in silico analysis
underscores the fact that the mutant polypeptide is very
different in both sequence and predicted secondary structure
from the wild-type K6a tail domain, consistent with a
dominant-negative gain-of-function mutation, as seen in
other keratinizing disorders due to C-terminal frameshift
mutations in K1 (Sprecher et al., 2001, 2003; Richardson et al.,
2006) or K5 (Sprecher et al., 2003). In the case of loricrin
keratoderma, a similar C-terminal gain-of-function mutation has
been shown to lead to creation of a new nuclear localization
signal, which in turn leads to nuclear accumulation of mutant
protein (Ishida-Yamamoto et al., 2000). The mutant K6a
polypeptide sequence generated here was analyzed for
potential nuclear localization signal motifs (http://cubic.bioc.
columbia.edu/services/predictNLS/), but none were found.
Splice site mutations identified in five kindreds
Interestingly we also detected four previously unreported
splice site mutations (in five families) at the intron 1/exon 2
boundary of KRT6A. These are clearly inherited in an
autosomal dominant manner. Unfortunately, we were unable
to obtain mRNA from lesional skin that would allow analysis
of the effects of these genomic mutations on RNA splicing.
One possible predicted consequence of this type of mutation
is skipping of exon 2; however, as this is an out-of-frame
exon, its deletion would lead to a frameshift and premature
termination codon. This is unlikely to create a dominant-
negative mutant protein, because nonsense-mediated mRNA
decay is predicted to occur, leading to loss of expression of
this allele. In the case of KRT5 and KRT1, both of which are
type II keratin genes closely related to KRT6A, analogous
mutations have been reported affecting the intron 1 splice
sites (Rugg et al., 1999; Terron-Kwiatkowski et al., 2002). In
both these genes, the mutation led to activation of an
identical cryptic splice site in exon 1, producing a 66-
nucleotide (22 amino acid) in-frame deletion. Given the
strong sequence homology between these genes, it is
probable that a similar mechanism will also occur with these
KRT6A splice site mutations.
Nonsense mutations in a few PC families
In addition, two heterozygous nonsense mutations were also
identified in PC cases. One of these was identified in the 2B
domain of K6a, p.Gln435X, which is predicted to lead to
expression of a truncated dominant-negative K6a protein,
lacking the end of the rod domain and the tail domain.
Because this mutation is close to the natural stop codon of
K6a, it is likely to escape nonsense-mediated decay to some
extent and, therefore, be expressed as mutant polypeptide
(Frischmeyer and Dietz, 1999). Analogous mutations have
been seen in K5 in dominantly inherited epidermolysis
bullosa simplex (Muller et al., 1999; Livingston et al.,
2001). The other nonsense mutation was found within the
head domain of K16, p.Lys15X. Analogous premature
termination codon mutations just downstream of the ATG
codon have been reported in other dominant keratin
disorders, including K5 in Dowling–Degos disease (Betz
et al., 2006; Liao et al., 2007b) and in K14 in Naegeli
syndrome (Lugassy et al., 2006). Although it remains some-
what unclear whether these mutations act via haploinsuffi-
ciency or via expression of a dominant-negative mutant
protein through use of an alternative initiation codon
(McLean et al., 2003), it is however clear that they exhibit
dominant inheritance (Betz et al., 2006; Lugassy et al., 2006).
Unfortunately, in the case of the two nonsense mutations
identified here, it was not possible to obtain tissue to allow
analysis of mRNA or protein.
A spectrum of keratin mutations cause PC
For each of the four genes associated with PC, it has been
suggested that there are some codons that represent mutation
hotspots, as well as several rare or even family-specific muta-
tions. Our results confirm the previously identified mutation
hotspots and also identify 21 previously unreported mutations.
Table 1 summarizes the data from previous publications
(http://www.interfil.org) together with the data from this large
case series.
DISCUSSION
The mutation results from this PC case series of 90 families,
together with those from at least 131 previously reported
cases (http://www.interfil.org), provides a large data set for
analysis in terms of where mutations occur within the keratin
protein, the most common mutations, the types of mutations
found, and allows for preliminary genotype–phenotype





recurrent mutations Most common mutation site
KRT6A 39 13 K6a p.Asn171—as missense or deletion mutation (K6a p.Asn172del), this codon is mutated in 46%
of those with KRT6A mutations, of which p.Asn172del accounts for 30% of all KRT6A mutations
KRT16 19 8 K16 p.Leu132Pro in 23% of families with KRT16 mutations
KRT17 22 8 K17 p.Asn92Ser in 36% of families with KRT17 mutations
KRT6B 4 1 K6b p.Glu472Lys in 71% of families with KRT6B mutations
www.jidonline.org 1021
NJ Wilson et al.
Pachyonychia Congenita
correlation. All cases with confirmed PC have a mutation in
one of the four keratin genes associated with this disease,
KRT6A, KRT6B, KRT16, and KRT17. In the course of running
the international mutation screening service for PC, in
concert with the IPCRR, we have received a small number
of samples from isolated cases or families in which no
mutation was found in these four keratin genes. In these
cases, careful review of the clinical phenotype by the
International Pachyonychia Congenita Consortium clinicians
often has often led to correction of the diagnosis, confirmed
by analysis of other keratin genes or non-keratin genes. For
example, a few cases, in which there is alopecia in addition
to nail dystrophy, have turned out to carry heterozygous
connexin-30 mutations (Lamartine et al., 2000; Smith et al.,
2002; van Steensel et al., 2003). Thus, Clouston syndrome
should be considered in the differential diagnosis for PC.
Similarly, a few families presenting with painful but very
limited, circumscribed focal plantar keratoderma, with
minimal or absent nail changes, have recently been shown
to have mutations in the gene encoding K6c (KRT6C; Wilson
et al., 2010). Taking these families into account, we have a
small number of families (o5%) in which careful clinical
evaluation is consistent with a diagnosis of PC and in whom
we cannot detect a mutation in any exon or splice sites of the
four PC keratin genes. Genetic linkage analysis in at least one
such family has yielded statistically significant linkage to the
vicinity of a keratin gene cluster (FJD Smith, unpublished
data), and so we conclude that there are either intronic or
genomic deletion/rearrangement mutations that are missed
by conventional PCR analysis, or that at least one other
keratin gene or a nearby related gene can lead to a PC-like
phenotype in a minority of cases. Sequence analysis of these
cases is ongoing in the laboratory.
All PC causative mutations found to date are heterozygous
changes that exhibit autosomal dominant inheritance with a
proven, or very probable, dominant-negative pathomechan-
ism. It is important to note that no recessive cases of PC have
been confirmed at the molecular level, despite a few case
reports appearing in the literature, in which, for example,
recessive inheritance may have been suggested by coin-
cidental consanguinity. It is therefore important that case
reports of already characterized genetic diseases be backed
up by molecular analysis, otherwise the literature may
become misleading. The recurrence risk of a sporadic case
of a dominant disorder is very low (involving only the risk of
gonadal mosaicism) which is difficult to estimate with
certainty. In the dominant disorder achondroplasia OMIM
no. 100800, this is of the order of one in a few hundred
(Mettler and Fraser, 2000); however, in epidermolysis bullosa
simplex, this has been estimated at 2–5% (Pfendner et al.,
2005). In contrast, the recurrence risk for a recessive condition
is as high as 25%. Thus, there are important genetic counseling
implications in the correct assignation of inheritance patterns.
So far, we have confirmed gonadal mosaicism in only one PC
family out of 199 analyzed from the IPCRR.
The majority of the mutations causing PC are located in
one of the helix boundary motifs of the mutated protein, and
most of the causative variants are missense or small in-frame
insertion–deletion mutations. Less common types identified
include splice site and premature termination codon muta-
tions. There are a number of mutation ‘hotspot’ codons for
each of the keratin genes associated with PC as well as
mutations that appear to be family specific (Table 1). The
most commonly mutated codon is K6a p.Asn171, either as a
missense mutation (e.g. p.Asn171Lys and p.Asn171Ser) or as
a deletion mutation (designated as p.Asn172del using the
Human Genome Variation Society guidelines; http://www.
hgvs.org). Approximately half of the families with identified
KRT6A mutations have a mutation at this site; the most
common PC mutation is the p.Asn172del mutation that, to
date, has been found in 32 out of 221 PC families (14%) with
known mutations (http://www.interfil.org and this study).
Despite the increased number of genotyped individuals
and families, there is no apparent correlation between the
clinical features observed and the protein domain harboring
the mutation in PC. Nevertheless, there are two mutations in
KRT16 in which the actual amino acid substitution appears
to correlate with the severity of the clinical phenotype
(see Fu et al., 2011). There are also some differences in
clinical features depending on the gene involved, such as the
presence of natal teeth in many, but not all, individuals with
KRT17 mutations (Eliason et al., unpublished). In PC, there
can also be variation in clinical severity between mutations in
the same gene and even between individuals with the same
mutation. Polymorphisms, copy number variation, environ-
mental factors, lifestyle, and patient care may account for
some of this clinical variation. Therefore, an important
conclusion of this large study of a keratin disorder is that
PC can really be considered as a spectrum of phenotypes
ranging from very mild to more severe, in which (a) the
particular gene involved appears to have a moderate
influence on phenotype and (b) the specific mutation
generally appears to have little influence on phenotype.
The detailed clinical information that is obtained by the
IPCRR also identified several cases, which were not included
in this study, that presented with both typical and atypical
features of PC and that were unlikely due to a mutation in any
of the four keratin genes, KRT6A, KRT6B, KRT16, or KRT17.
These were analyzed for mutations in other candidate genes.
For example, several families presented with varying degrees
of alopecia in addition to some features typical of PC, which
was suggestive of Clouston syndrome (Lamartine et al., 2000;
Smith et al., 2002; van Steensel et al., 2003) and mutations
were subsequently identified in GJB6 (which encodes con-
nexin 30). Another candidate gene considered for individuals
presenting with palmoplantar keratoderma was the third K6
gene (KRT6C). We have identified mutations in KRT6C in
several families presenting with palmoplantar keratoderma,
but with only mild/no nail changes (Wilson et al., 2010).
Genetic analysis of individuals with PC not only confirms
their clinical diagnosis but also aids in genetic counseling.
The identification of mutations is especially important for the
design of future mutation-specific and/or gene-specific
therapies and, hence, the large, well-phenotyped, and fully
genotyped case series we report here is an invaluable
resource for future clinical trials.
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Genomic DNA was obtained with informed consent and ethical
approval by an institutional review board that complies with all
principles of the Helsinki Accord (Western IRB Study no. 20040468).
Genomic DNA was extracted from peripheral blood lymphocytes
using standard procedures or from saliva collected in an Oragene
DNA sample collection kit (DNA Genotek, Ontario, Canada) and
extracted according to the manufacturer’s protocol.
Mutation detection
The coding regions of KRT6A, KRT6B, KRT16, and KRT17 were
amplified using primers specific to the respective functional genes to
avoid amplification of KRT6C or pseudogenes (Supplementary Table
S2 online). All primers were checked for single-nucleotide poly-
morphisms using Diagnostic SNPCheck (http://www.ngrl.org.uk/
Manchester) and some were modified from our previous publica-
tions (Smith et al., 2005) to increase specificity. For each gene, there
are two primer sets for the mutation hotspot exons to overcome
the potential problem of very rare or as yet unidentified single-
nucleotide polymorphisms in primers designed to amplify these
regions. Previously unreported mutations were excluded from at
least 90 control DNA samples (180 chromosomes) by sequencing or
restriction enzyme digests. For full-length genomic PCR reactions,
Takara buffer and LA Taq polymerase (Lonza Biologics PLC, Slough,
UK) were used and for the smaller PCR reactions and HotStarTaq
DNA Polymerase and buffer system (Qiagen, Crawley, UK) were
used according to the manufacturer’s instructions. Specific PCR
conditions for each primer set are available on request. PCR
products were purified using QiaQuick PCR spin columns (Qiagen)
or ExoSAP (using Exonuclease 1 and Shrimp Antartic Phosphatase,
New England Biolabs, Hitchin, Herts, UK), and sequenced using
internal primers on an ABI 3100 Automated DNA sequencing
machine (Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions.
Protein bioinformatics
Hydrophobicity (Kyte–Doolittle analysis) and protein secondary
structure predictions (Robson–Garnier analysis) were performed
using the Protein Analysis Toolkit function within the MacVector
9.0 software package (MacVector, Cary, NC).
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